Published in PLoS Genet on August 30, 2012
Non-coding RNA in neural function, disease, and aging. Front Genet (2015) 0.97
12q24 locus association with type 1 diabetes: SH2B3 or ATXN2? World J Diabetes (2014) 0.95
Invited review: decoding the pathophysiological mechanisms that underlie RNA dysregulation in neurodegenerative disorders: a review of the current state of the art. Neuropathol Appl Neurobiol (2015) 0.85
NeuroGeM, a knowledgebase of genetic modifiers in neurodegenerative diseases. BMC Med Genomics (2013) 0.81
The promise and perils of HDAC inhibitors in neurodegeneration. Ann Clin Transl Neurol (2014) 0.81
Ataxin-2 (Atxn2)-Knock-Out Mice Show Branched Chain Amino Acids and Fatty Acids Pathway Alterations. Mol Cell Proteomics (2016) 0.81
Ataxin-2 regulates RGS8 translation in a new BAC-SCA2 transgenic mouse model. PLoS Genet (2015) 0.80
A knockin mouse model of spinocerebellar ataxia type 3 exhibits prominent aggregate pathology and aberrant splicing of the disease gene transcript. Hum Mol Genet (2014) 0.80
Large-scale RNA interference screening in mammalian cells identifies novel regulators of mutant huntingtin aggregation. PLoS One (2014) 0.79
Potentiation of neurotoxicity in double-mutant mice with Pink1 ablation and A53T-SNCA overexpression. Hum Mol Genet (2014) 0.79
Both ubiquitin ligases FBXW8 and PARK2 are sequestrated into insolubility by ATXN2 PolyQ expansions, but only FBXW8 expression is dysregulated. PLoS One (2015) 0.77
Atxn2 Knockout and CAG42-Knock-in Cerebellum Shows Similarly Dysregulated Expression in Calcium Homeostasis Pathway. Cerebellum (2017) 0.77
Aggregation of Polyglutamine-expanded Ataxin 7 Protein Specifically Sequesters Ubiquitin-specific Protease 22 and Deteriorates Its Deubiquitinating Function in the Spt-Ada-Gcn5-Acetyltransferase (SAGA) Complex. J Biol Chem (2015) 0.77
Motor Dysfunctions and Neuropathology in Mouse Models of Spinocerebellar Ataxia Type 2: A Comprehensive Review. Front Neurosci (2016) 0.75
Mammalian ataxin-2 modulates translation control at the pre-initiation complex via PI3K/mTOR and is induced by starvation. Biochim Biophys Acta (2016) 0.75
Regulation of mRNA Translation by MID1: A Common Mechanism of Expanded CAG Repeat RNAs. Front Cell Neurosci (2016) 0.75
The FOXP2-Driven Network in Developmental Disorders and Neurodegeneration. Front Cell Neurosci (2017) 0.75
Polyglutamine spinocerebellar ataxias - from genes to potential treatments. Nat Rev Neurosci (2017) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res (2002) 76.95
Trinucleotide repeat disorders. Annu Rev Neurosci (2007) 9.45
Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature (2010) 5.26
Homologues of the Caenorhabditis elegans Fox-1 protein are neuronal splicing regulators in mammals. Mol Cell Biol (2005) 5.03
Mammalian stress granules and processing bodies. Methods Enzymol (2007) 4.76
Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat Genet (1996) 4.16
Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev (2010) 3.69
Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat Genet (1996) 3.26
Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. Nat Genet (1996) 3.07
Ataxin-2 interacts with the DEAD/H-box RNA helicase DDX6 and interferes with P-bodies and stress granules. Mol Biol Cell (2007) 2.30
The splicing regulator Rbfox1 (A2BP1) controls neuronal excitation in the mammalian brain. Nat Genet (2011) 2.10
The natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year follow-up study. Neurology (2011) 2.06
Purkinje cell expression of a mutant allele of SCA1 in transgenic mice leads to disparate effects on motor behaviors, followed by a progressive cerebellar dysfunction and histological alterations. J Neurosci (1997) 1.99
Exercise and genetic rescue of SCA1 via the transcriptional repressor Capicua. Science (2011) 1.96
Loss of endogenous androgen receptor protein accelerates motor neuron degeneration and accentuates androgen insensitivity in a mouse model of X-linked spinal and bulbar muscular atrophy. Hum Mol Genet (2006) 1.93
Local RNA translation at the synapse and in disease. J Neurosci (2011) 1.83
Expression of ataxin-2 in brains from normal individuals and patients with Alzheimer's disease and spinocerebellar ataxia 2. Ann Neurol (1999) 1.77
Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human. Nat Genet (2000) 1.67
Ataxin-2 repeat-length variation and neurodegeneration. Hum Mol Genet (2011) 1.60
The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. J Neurochem (2009) 1.52
The utility F-box for protein destruction. Cell Mol Life Sci (2008) 1.43
Ataxin-2 and its Drosophila homolog, ATX2, physically assemble with polyribosomes. Hum Mol Genet (2006) 1.43
Altered transcriptional regulation in cells expressing the expanded polyglutamine androgen receptor. Hum Mol Genet (2002) 1.41
An OBSL1-Cul7Fbxw8 ubiquitin ligase signaling mechanism regulates Golgi morphology and dendrite patterning. PLoS Biol (2011) 1.40
dAtaxin-2 mediates expanded Ataxin-1-induced neurodegeneration in a Drosophila model of SCA1. PLoS Genet (2007) 1.38
The N-terminal domain of the human TATA-binding protein plays a role in transcription from TATA-containing RNA polymerase II and III promoters. EMBO J (1994) 1.37
Spinocerebellar ataxia type 2 with parkinsonism in ethnic Chinese. Neurology (2000) 1.31
Autosomal dominant cerebellar ataxia: clinical analysis of 263 patients from a homogeneous population in Holguín, Cuba. Neurology (1990) 1.30
Possible function of the ADAM1a/ADAM2 Fertilin complex in the appearance of ADAM3 on the sperm surface. J Biol Chem (2004) 1.29
An integrative approach to gain insights into the cellular function of human ataxin-2. J Mol Biol (2004) 1.26
Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. Hum Mol Genet (2011) 1.24
Modelling brain diseases in mice: the challenges of design and analysis. Nat Rev Genet (2003) 1.20
Assessment of the nutrition status of patients with Huntington's disease. Nutrition (2004) 1.20
Trinucleotide repeats and neurodegenerative disease. Brain (2004) 1.19
The modulation of Amyotrophic Lateral Sclerosis risk by ataxin-2 intermediate polyglutamine expansions is a specific effect. Neurobiol Dis (2011) 1.12
Recognition of nonsense mRNA: towards a unified model. Biochem Soc Trans (2008) 1.11
Spinocerebellar ataxia 2 (SCA2): morphometric analyses in 11 autopsies. Acta Neuropathol (1999) 1.11
Disruption of the Fbxw8 gene results in pre- and postnatal growth retardation in mice. Mol Cell Biol (2007) 1.10
Are interrupted SCA2 CAG repeat expansions responsible for parkinsonism? Neurology (2007) 1.10
Insulin receptor and lipid metabolism pathology in ataxin-2 knock-out mice. Hum Mol Genet (2008) 1.07
Weight loss in neurodegenerative disorders. J Neurol (2009) 1.06
General RNA-binding proteins have a function in poly(A)-binding protein-dependent translation. EMBO J (2008) 1.06
Ataxin-2 associates with the endocytosis complex and affects EGF receptor trafficking. Cell Signal (2008) 1.06
The role of the SCA2 trinucleotide repeat expansion in 89 autosomal dominant cerebellar ataxia families. Frequency, clinical and genetic correlates. Brain (1998) 1.03
Spinocerebellar ataxia type 2. Genotype and phenotype in German kindreds. Arch Neurol (1997) 0.98
Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis. Arch Toxicol (2008) 0.97
Ataxin-2 associates with rough endoplasmic reticulum. Exp Neurol (2008) 0.96
Neurodegeneration: An expansion in ALS genetics. Nature (2010) 0.94
Parkin is an E3 ubiquitin-ligase for normal and mutant ataxin-2 and prevents ataxin-2-induced cell death. Exp Neurol (2006) 0.93
Spinocerebellar ataxia type 2. Handb Clin Neurol (2012) 0.92
The KRAB-containing zinc-finger transcriptional regulator ZBRK1 activates SCA2 gene transcription through direct interaction with its gene product, ataxin-2. Hum Mol Genet (2010) 0.92
Complex phenotypes in an Indian family with homozygous SCA2 mutations. Ann Neurol (2004) 0.88
Pathoanatomy of cerebellar degeneration in spinocerebellar ataxia type 2 (SCA2) and type 3 (SCA3). Cerebellum (2012) 0.88
Spinocerebellar ataxia type 2 (SCA2) in an Egyptian family presenting with polyphagia and marked CAG expansion in infancy. J Neurol (2008) 0.87
Subthalamic-thalamic DBS in a case with spinocerebellar ataxia type 2 and severe tremor-A unusual clinical benefit. Mov Disord (2007) 0.87
Saccade velocity is controlled by polyglutamine size in spinocerebellar ataxia 2. Ann Neurol (2004) 0.85
Depletion of cellular poly (A) binding protein prevents protein synthesis and leads to apoptosis in HeLa cells. Biochem Biophys Res Commun (2011) 0.85
Neuronal intranuclear inclusions in SCA2: a genetic, morphological and immunohistochemical study of two cases. Brain (2002) 0.85
Stages of sleep pathology in spinocerebellar ataxia type 2 (SCA2). Neurology (2006) 0.85
Anatomically based guidelines for systematic investigation of the central somatosensory system and their application to a spinocerebellar ataxia type 2 (SCA2) patient. Neuropathol Appl Neurobiol (2003) 0.84
Paradoxical absence of nuclear inclusion in cerebellar Purkinje cells of hereditary ataxias linked to CAG expansion. J Neurol Neurosurg Psychiatry (2002) 0.84
Consistent affection of the central somatosensory system in spinocerebellar ataxia type 2 and type 3 and its significance for clinical symptoms and rehabilitative therapy. Brain Res Rev (2006) 0.83
Histone acetylation, acetyltransferases, and ataxia--alteration of histone acetylation and chromatin dynamics is implicated in the pathogenesis of polyglutamine-expansion disorders. Adv Protein Chem Struct Biol (2010) 0.83
Involvement of the cranial nerves and their nuclei in spinocerebellar ataxia type 2 (SCA2). Acta Neuropathol (2005) 0.82
Spinocerebellar ataxias types 2 and 3: degeneration of the pre-cerebellar nuclei isolates the three phylogenetically defined regions of the cerebellum. J Neural Transm (Vienna) (2005) 0.81
Spinocerebellar ataxia type 2 (SCA2): identification of early brain degeneration in one monozygous twin in the initial disease stage. Cerebellum (2011) 0.81
Phenotype variation correlates with CAG repeat length in SCA2--a study of 28 Japanese patients. J Neurol Sci (1998) 0.80
Involvement of the auditory brainstem system in spinocerebellar ataxia type 2 (SCA2), type 3 (SCA3) and type 7 (SCA7). Neuropathol Appl Neurobiol (2008) 0.79
Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging (2002) 22.40
Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science (2004) 15.91
Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology (2002) 7.73
Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res (2004) 7.06
Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J Neurosci (2007) 5.68
Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature (2010) 5.26
Mutations in a human ROBO gene disrupt hindbrain axon pathway crossing and morphogenesis. Science (2004) 3.01
Ascorbic-acid transporter Slc23a1 is essential for vitamin C transport into the brain and for perinatal survival. Nat Med (2002) 2.90
Where does parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol (2002) 2.46
Knockdown of transactive response DNA-binding protein (TDP-43) downregulates histone deacetylase 6. EMBO J (2009) 2.37
Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol (2002) 2.37
Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res (2006) 2.36
Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov Disord (2006) 2.31
Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology (2012) 2.18
TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice. Glia (2008) 1.97
Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6. Neurobiol Dis (2006) 1.96
Genome-wide association study of intracranial aneurysm identifies three new risk loci. Nat Genet (2010) 1.86
Spinocerebellar ataxia 2 (SCA2). Cerebellum (2008) 1.84
Mutations in CIZ1 cause adult onset primary cervical dystonia. Ann Neurol (2012) 1.82
Parkinson patient fibroblasts show increased alpha-synuclein expression. Exp Neurol (2008) 1.79
Neuroanatomical characteristics of the human pre-Bötzinger complex and its involvement in neurodegenerative brainstem diseases. Brain (2010) 1.75
The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J Biol Chem (2004) 1.75
Antibodies to MHC class I induce autoimmunity: role in the pathogenesis of chronic rejection. J Immunol (2009) 1.74
Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. PLoS One (2009) 1.71
Respiratory viral infection in obliterative airway disease after orthotopic tracheal transplantation. Ann Thorac Surg (2006) 1.63
Mapping local hippocampal changes in Alzheimer's disease and normal ageing with MRI at 3 Tesla. Brain (2008) 1.61
Two types of sporadic cerebral amyloid angiopathy. J Neuropathol Exp Neurol (2002) 1.51
Reversible cardiac sympathectomy by high thoracic epidural anesthesia improves regional left ventricular function in patients undergoing coronary artery bypass grafting: a randomized trial. Arch Surg (2003) 1.50
Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7. Prog Neurobiol (2013) 1.40
Independent and joint effects of the MAPT and SNCA genes in Parkinson disease. Ann Neurol (2011) 1.40
Brain pathology of spinocerebellar ataxias. Acta Neuropathol (2012) 1.39
Resting state fMRI reveals increased subthalamic nucleus-motor cortex connectivity in Parkinson's disease. Neuroimage (2011) 1.37
Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Mol Cell Neurosci (2003) 1.37
SCA3: neurological features, pathogenesis and animal models. Cerebellum (2008) 1.31
Molecular karyotyping of patients with unexplained mental retardation by SNP arrays: a multicenter study. Hum Mutat (2009) 1.30
Quantitative mapping of T1 and T2* discloses nigral and brainstem pathology in early Parkinson's disease. Neuroimage (2010) 1.26
Vulnerability of cortical neurons to Alzheimer's and Parkinson's diseases. J Alzheimers Dis (2006) 1.25
Decreased expression of Drp1 and Fis1 mediates mitochondrial elongation in senescent cells and enhances resistance to oxidative stress through PINK1. J Cell Sci (2010) 1.25
Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. Hum Mol Genet (2011) 1.24
On the structure of thiolate-protected Au25. J Am Chem Soc (2008) 1.22
Cognitive decline correlates with neuropathological stage in Parkinson's disease. J Neurol Sci (2006) 1.19
Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease. Brain (2009) 1.16
A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice. PLoS One (2010) 1.13
The modulation of Amyotrophic Lateral Sclerosis risk by ataxin-2 intermediate polyglutamine expansions is a specific effect. Neurobiol Dis (2011) 1.12
The brainstem pathologies of Parkinson's disease and dementia with Lewy bodies. Brain Pathol (2014) 1.11
Divide and protect: capping gold nanoclusters with molecular gold-thiolate rings. J Phys Chem B (2006) 1.10
Clinical and positron emission tomography of Parkinson's disease caused by LRRK2. Ann Neurol (2005) 1.09
Common variant near the endothelin receptor type A (EDNRA) gene is associated with intracranial aneurysm risk. Proc Natl Acad Sci U S A (2011) 1.08
Insulin receptor and lipid metabolism pathology in ataxin-2 knock-out mice. Hum Mol Genet (2008) 1.07
Ataxin-2 associates with the endocytosis complex and affects EGF receptor trafficking. Cell Signal (2008) 1.06
The first genomewide interaction and locus-heterogeneity linkage scan in bipolar affective disorder: strong evidence of epistatic effects between loci on chromosomes 2q and 6q. Am J Hum Genet (2007) 1.04
Current understanding of the role of high-density lipoproteins in atherosclerosis and senescence. Expert Rev Cardiovasc Ther (2005) 1.04
Loss of mitochondrial peptidase Clpp leads to infertility, hearing loss plus growth retardation via accumulation of CLPX, mtDNA and inflammatory factors. Hum Mol Genet (2013) 1.03
First appraisal of brain pathology owing to A30P mutant alpha-synuclein. Ann Neurol (2010) 1.03
Vascular risk factors in sudden hearing loss. Thromb Haemost (2006) 1.02
Exacerbated synucleinopathy in mice expressing A53T SNCA on a Snca null background. Neurobiol Aging (2005) 1.02
Primary skin fibroblasts as a model of Parkinson's disease. Mol Neurobiol (2012) 1.01
Diffusion tensor imaging of white matter involvement in essential tremor. Hum Brain Mapp (2010) 0.99
High prevalence of thorn-shaped astrocytes in the aged human medial temporal lobe. Neurobiol Aging (2004) 0.97
Gene expression profiles reveal an upregulation of E2F and downregulation of interferon targets by HPV18 but no changes between keratinocytes with integrated or episomal viral genomes. Virology (2006) 0.97
Ataxin-2 associates with rough endoplasmic reticulum. Exp Neurol (2008) 0.96
De novo MECP2 duplication in two females with random X-inactivation and moderate mental retardation. Eur J Hum Genet (2011) 0.96
ATXN2 and its neighbouring gene SH2B3 are associated with increased ALS risk in the Turkish population. PLoS One (2012) 0.94
Theoretical characterization of cyclic thiolated gold clusters. J Am Chem Soc (2006) 0.94
Inverse relationship between cerebrovascular lesions and severity of lewy body pathology in patients with lewy body diseases. J Neuropathol Exp Neurol (2010) 0.93
A-type and B-type natriuretic peptides in cardiac surgical procedures. Anesth Analg (2004) 0.92
Spinocerebellar ataxia type 3 (SCA3): thalamic neurodegeneration occurs independently from thalamic ataxin-3 immunopositive neuronal intranuclear inclusions. Brain Pathol (2006) 0.91
Prism adaptation in spinocerebellar ataxia type 2. Neuropsychologia (2007) 0.91
Haemoglobin-related mortality in patients undergoing percutaneous coronary interventions. Eur Heart J (2003) 0.91
Axonal inclusions in spinocerebellar ataxia type 3. Acta Neuropathol (2010) 0.91
A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. J Med Genet (2012) 0.90
Ataxin-2 promotes apoptosis of human neuroblastoma cells. Oncogene (2003) 0.90
Genomewide scan and fine-mapping linkage studies in four European samples with bipolar affective disorder suggest a new susceptibility locus on chromosome 1p35-p36 and provides further evidence of loci on chromosome 4q31 and 6q24. Am J Hum Genet (2005) 0.90
Alpha-synuclein deficiency leads to increased glyoxalase I expression and glycation stress. Cell Mol Life Sci (2010) 0.89
Protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants. Neurobiol Aging (2013) 0.89
Genome-wide expression profiling of the retinoschisin-deficient retina in early postnatal mouse development. Invest Ophthalmol Vis Sci (2007) 0.89